Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old Population

Randomized, Double-blind, Controlled Phase Ⅰ and Phase Ⅲ Clinical Trial to Evaluate the Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old Population

This is a randomized, double-blind, positive controlled design clinical trial of tetanus vaccine, adsorbed manufactured by Sinovac Life Sciences Co., Ltd.The purpose of this study is to evaluate the safety and immunogenicity of tetanus vaccine, adsorbed in 18~44 years old population.

Study Overview

• Status: Recruiting
• Conditions: Tetanus
• Intervention / Treatment: Biological: Investigational tetanus vaccine, adsorbed; Biological: Control tetanus vaccine, adsorbed

Detailed Description

This is a randomized, double-blind, positive controlled design clinical trial of tetanus vaccine, adsorbed.The purpose of this study is to evaluate the safety and immunogenicity of tetanus vaccine, adsorbed in 18~44 years old population.The study will conduct in two phases.A total of 1260 subjects including 60 subjects in phase Ⅰ and 1200 subjects in phase III will be enrolled.All of subjects in phase Ⅰ and phase III will be randomly assigned 2 groups in a 1:1 ratio to receive one dose of experimental vaccine or control vaccine.

• Study Type: Interventional
• Enrollment (Estimated): 1260
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Zhiqiang Xie; Phone Number: 13526534586; Email: xiezqshang@163.com

Study Locations

• China
  • Henan
    • Shangqiu, Henan, China, 450016
      • Recruiting
      • Liangyuan District Center for Disease Control and Prevention
      • Contact: Qiang Liu; Phone Number: 13569386065; Email: 44477039@qq.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Healthy aldults aged 18-44 months;
• Proven legal identity;
• Subjects have the ability to understand and agree to sign the informed consent form.

Exclusion Criteria:

• Armpit temperature of persons with fever on the day of experimental vaccine administration>37.0 ℃;
• Previous history of tetanus infection;
• Has received tetanus vaccines or vaccines containing tetanus toxoid antigen (DTP, DTP, meningococcal conjugate vaccine, etc.) within the last 5 years, or has received a tetanus immunoglobulin or tetanus antitoxin within the last 6 months;
• Women who are lactating, pregnant (with a positive urine pregnancy test) or planning to become pregnant within the last 3 months;
• History of asthma, allergy to vaccines or vaccine components, and severe adverse reactions to vaccines, such as urticaria, dyspnea, angioedema, or abdominal pain;
• Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.;
• Have congenital or acquired immunodeficiency such as HIV infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), juvenile rheumatoid arthritis (JRA);
• Thyroid disease or history of thyroidectomy, asplenia,functional asplenia, asplenia or splenectomy resulting from any condition;
• Severe chronic diseases,such as severe cardiovascular diseases, hypertension(Systolic blood pressure ≥140mmHg and/or diastolic blood pressure ≥90mmHg) and diabetes that cannot be controlled by drugs, liver or kidney diseases,malignant tumors, etc;
• Currently suffering from or have suffered from encephalopathy (such as congenital brain hypoplasia, brain trauma, brain tumor, cerebral hemorrhage, cerebral infarction, brain infection, chemical poisoning, etc.); A history of convulsions, epilepsy, psychosis or a family history of psychosis, and other serious neurological disorders;
• Diagnosed abnormal blood coagulation function (e.g. coagulation factor deficiency, coagulation disorders, abnormal platelets) or obvious bruising or coagulation disorders;
• Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) in the past 6 months;
• A long history of alcohol or drug abuse;
• Receipt of blood products within in the past 3 months;
• Receipt of attenuated live vaccines in the past 14 days;
• Receipt of inactivated or subunit vaccines in the past 7 days;
• Acute onset of various acute diseases or chronic diseases in the last 7 days;
• Participating in clinical studies of other vaccines or drugs;
• According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Experimental Group; 630 Participants (including 30 subjects in phaseⅠ, 600 subjects in phase Ⅲ ) will receive one dose of experimental vaccine or control vaccine.	Biological: Investigational tetanus vaccine, adsorbed; The investigational vaccine was manufactured by Sinovac Life Sciences Co., Ltd. There is not less than 40IU tetanus toxoid in 0.5ml per dose.
Active Comparator: Control Group; 630 Participants (including 30 subjects in phaseⅠ, 600 subjects in phase Ⅲ ) will receive one dose of experimental vaccine or control vaccine.	Biological: Control tetanus vaccine, adsorbed; The control tetanus vaccine, adsorbed was manufactured by Chengdu Olymvax Biopharmaceuticals Inc.There is not less than 40IU tetanus toxoid in 0.5ml per dose.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of adverse reactions	Incidence of adverse reactions within 30 days after vaccination.	within 30 days after vaccination
Incidence of local or systemic adverse reactions	Incidence of local or systemic adverse reactions within 7 days after vaccination.	Within 7 days after vaccination
Incidence of grade 3 and above adverse reactions	Incidence of grade 3 and above adverse reactions within 30 days after vaccination	Within 30 days after vaccination
Incidence of SAE related to vaccination	Incidence of SAE related to vaccination from the beginning of vaccination to 6 months after vaccination.	From the beginning of vaccination to 6 months after vaccination

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The seroprotective rate of anti-tetanus toxiod antibody	The seroprotective rate of anti-tetanus toxiod antibody 30 days after vaccination.	30 days after vaccination
Long-term seroprotective rate of anti-tetanus toxiod antibody	Long-term seroprotective rate of anti-tetanus toxiod antibody 30 days after vaccination.	30 days after vaccination
Seroconversion rate of anti-tetanus toxiod antibody	Seroconversion rate of anti-tetanus toxiod antibody 30 days after vaccination.	30 days after vaccination
GMC of anti-tetanus toxiod antibody	GMC of anti-tetanus toxiod antibody 30 days after vaccination.	30 days after vaccination
GMC increase folds (GMI) of anti-tetanus toxiod antibody	GMC increase folds (GMI) of anti-tetanus toxiod antibody 30 days after vaccination.	30 days after vaccination

Collaborators and Investigators

• Sponsor: Sinovac Life Sciences Co., Ltd.
• Investigators: Principal Investigator: Zhiqing Xie, Henan Provincial Center for Disease Prevention and Control

Study record dates

Study Major Dates

• Study Start (Actual): September 1, 2023
• Primary Completion (Estimated): September 1, 2024
• Study Completion (Estimated): March 30, 2025

Study Registration Dates

• First Submitted: September 15, 2023
• First Submitted That Met QC Criteria: September 15, 2023
• First Posted (Actual): September 22, 2023

Study Record Updates

• Last Update Posted (Actual): October 18, 2023
• Last Update Submitted That Met QC Criteria: October 16, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Metabolic Diseases; Nervous System Diseases; Infections; Neurologic Manifestations; Bacterial Infections; Bacterial Infections and Mycoses; Gram-Positive Bacterial Infections; Neuromuscular Manifestations; Clostridium Infections; Hypocalcemia; Calcium Metabolism Disorders; Tetanus; Tetany; Physiological Effects of Drugs; Immunologic Factors; Vaccines
• Other Study ID Numbers: PRO-TT-3001

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No